Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer – The ASCO Post

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer  The ASCO PostPadcev-Keytruda combo aces another bladder cancer trial as MIBC landscape becomes more complex  Fierce PharmaPADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer  Yahoo FinanceMayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer  Mayo Clinic News NetworkLeslie Ballas, MD, highlights trial of risk-adapted bladder preservation in MIBC  Urology Times